Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$1.6 billion.

  • Arrowhead Pharmaceuticals' Retained Earnings rose 1124.56% to -$1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.6 billion, marking a year-over-year increase of 1124.56%. This contributed to the annual value of -$1.6 billion for FY2025, which is 10.03% down from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Retained Earnings stood at -$1.6 billion, which was up 1124.56% from -$1.6 billion recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Retained Earnings high stood at -$551.4 million for Q1 2021, and its period low was -$1.8 billion during Q4 2024.
  • Its 5-year average for Retained Earnings is -$1.1 billion, with a median of -$971.2 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 5878.05% in 2024, then surged by 1124.56% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Retained Earnings stood at -$707.6 million in 2021, then fell by 21.84% to -$862.1 million in 2022, then crashed by 34.43% to -$1.2 billion in 2023, then crashed by 55.2% to -$1.8 billion in 2024, then grew by 11.25% to -$1.6 billion in 2025.
  • Its Retained Earnings was -$1.6 billion in Q4 2025, compared to -$1.6 billion in Q3 2025 and -$1.6 billion in Q2 2025.